# Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer

> **NCT01689558** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Jin Feng** · enrollment: 60 (estimated)

## Conditions studied

- 1、Enough Cases
- 2、Elekta Precise 1343 Digital Control Electron Linear Accelerator
- Can Undertake Nasopharyngeal Carcinoma Specimens in the Materia，
- Image Department of Nose Pharynx Ministry MRI Dynamic Testing,

## Interventions

- **DRUG:** Recombine Endostatin

## Key facts

- **NCT ID:** NCT01689558
- **Lead sponsor:** Jin Feng
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2015-01
- **Final completion:** 2017-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01689558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01689558, "Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01689558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*